On 7 August 2024, Novo Nordisk A/S will announce the financial results for the first six months of 2024.
An earnings call will follow the announcement at:
13:00-14:00 (CEST)
12:00-13:00 (BST)
07:00-08:00am (EDT)
The earnings call will be accessible at the following link: https://edge.media-server.com/mmc/p/n7putxx6
To access the earnings call, please register the following link to ask questions: https://register.vevent.com/register/BI1cfed0667566491e8b1faf819f4f9a2d
Novo Nordisk A/S will host a London conference call on 8 August 2024 in relation to the financial results for the first six months of 2024 announced on 7 August 2024.
The London conference call will be at:
12:15-13:30 (CEST)
11.15-12:30 (BST)
06:15-07:30am (EDT)
The London conference call will be accessible at the following link: https://edge.media-server.com/mmc/p/fo8eytnc
We announced our financial results for the three first months of 2024.
Novo Nordisk A/S announced financial results for the full year of 2023:
Novo Nordisk A/S hosted a R&D investor call in relation to the
annual American Heart Association (AHA) conference. This year the
conference is hosted in in Philadelphia, US.
Novo Nordisk A/S hosted a R&D investor call in relation to the annual ADA conference. This year the conference is hosted in San Diego, CA.
Full-year 2022 financial results were published 01 February 2023, 7:30 CET:
The conference call took place 01 February 2023,
13:00 CET
In connection with ADA 82nd Scientific Sessions Novo Nordisk A/S will host an investor event.